| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Jun24 Quarterly Activities Statement and Appendix 4C
|
31 Jul 2024 5:28PM |
$0.016 |
$0.010 |
fallen by
37.50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- US Patent Approval for Nexusâ„¢ Technology
- World Rugby Performance Specification Achieved
- NRL Women teams deployed with Nexusâ„¢
- Updated concussion management protocol, SCAT6, deployed
- Signed $1.6m convertible note facility with Harmil Angel Investments
- Cash reserves of A$576k as of 30 June 2024
- Payments to related parties totaling A$54,776
- Corporate appointment of Henslow and Earl Eddings
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
US Patent Approved for Nexus Technology
|
30 Jul 2024 10:39AM |
$0.016 |
$0.010 |
fallen by
37.50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- US Patent Application US 17/753,356 approved
- HITIQ technology now supported by foundational IP protection in key jurisdiction
- Data categorization key aspect of IP related to field performance of technology
- Data categorization enables delivery of reliable field data
- Patent neutralizes noisy field environments and false positive data
- Patent unlocks commercial opportunities in the key target market
- Approval validates technology and secures major market entry
- Technology involves a custom calibrated mouthguard with impact sensors
- Legal announcement authorized by HITIQ Board of Directors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
HITIQ Mouthguard Technology Meets World Rugby Specification
|
18 Jul 2024 9:42AM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ meets World Rugby specification for instrumented mouthguards
- Approval enables use in global rugby union
- Target market opportunity spans 132 national member federations
- Technology enhances player safety via real-time data for head impact
- Commercial opportunities expected to rise from this approval
- HitIQ's Nexusâ„¢ mouthguard embedded with validated impact sensor technology
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Change of Director's Interest Notice - Phil Carulli
|
11 Jun 2024 3:34PM |
$0.023 |
$0.010 |
fallen by
56.52%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Notification regarding unquoted securities - HIQ
|
21 May 2024 11:30AM |
$0.020 |
$0.010 |
fallen by
50%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Convertible Note and Appointment of Advisors
|
20 May 2024 10:04AM |
$0.016 |
$0.010 |
fallen by
37.50%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ Limited announces the execution of a binding agreement for a Convertible Note to raise up to $1.5 million.
- The Convertible Note will be used to fund working capital and business growth initiatives.
- PAC Partners and KG Capital appointed as corporate advisors to assist with capital management and strategic initiatives.
- The Convertible Note includes terms such as conversion rights, interest rate, and maturity date.
- Funds raised will support commercial growth, partnerships, and product development.
- Company provides an update on its current cash position and financial outlook.
- Focus remains on achieving financial sustainability and operational growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Mar24 Quarterly Activities Statement and Appendix 4C
|
30 Apr 2024 6:14PM |
$0.026 |
$0.010 |
fallen by
61.54%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from operating activities increased to $0.46m in the March 2024 quarter, up from $0.36m in the December 2023 quarter.
- Secured new contracts and renewals with major sporting organizations and healthcare institutions.
- Launched new concussion management products and expanded into additional sports and healthcare markets.
- Maintained strong cash position with a balance of $4.5m at the end of the quarter.
- Demonstrated prudent cost control and operational efficiencies.
- Healthcare segment showed early traction, with new customer wins and growing interest.
- Focus remains on commercializing core technologies and scaling sales, particularly in the healthcare sector.
- Key priorities for the next quarter include further product rollouts, expanding market reach, and continued financial discipline.
- No payments were made to related parties during the quarter except for director fees and salaries.
- Outlook remains positive, with expected continued growth in revenue and customer base across core markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Notification of cessation of securities - HIQ
|
10 Apr 2024 2:36PM |
$0.029 |
$0.010 |
fallen by
65.52%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
HITIQ Granted New Australian Patent
|
4 Apr 2024 10:42AM |
$0.028 |
$0.010 |
fallen by
64.29%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ Limited (ASX: HIQ) has been granted a new Australian patent.
- The patent is for a method and system for detecting and monitoring brain injuries using sensor technology.
- The newly granted patent extends coverage for HitIQ’s core technology in Australia.
- The technology supports HitIQ’s existing product portfolio including the Nexus A9 mouthguard.
- This patent further strengthens HitIQ’s intellectual property protection and commercialisation potential.
- The news is seen as significant for the company’s position in sports technology and injury management.
- HitIQ’s CEO has commented that the patent grant is validation of their innovation and R&D efforts.
- The announcement highlights that HitIQ’s technology is used by professional and amateur sporting organisations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
NRL Adopt HITIQ Mouthguard Technology for 2024 Season
|
28 Mar 2024 11:49AM |
$0.025 |
$0.010 |
fallen by
60%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Notification of cessation of securities - HIQ
|
22 Mar 2024 4:32PM |
$0.024 |
$0.010 |
fallen by
58.33%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
R&D TAX INCENTIVE LOAN FACILITY
|
18 Mar 2024 3:14PM |
$0.025 |
$0.010 |
fallen by
60%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Half Yearly Report and Accounts
|
29 Feb 2024 1:01PM |
$0.026 |
$0.010 |
fallen by
61.54%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Report covers the half-year ended 31 December 2023.
- Principal activity is developing technology for head impact detection and monitoring in sports.
- Revenue increased modestly, but the company recorded a net loss.
- Ongoing investment in product development, sales, and marketing.
- Focus on international market expansion and operational scaling.
- Acknowledgement of risks including technology adoption, competition, and funding requirements.
- Emphasis on new strategic partnerships and ongoing business development.
- Management remains confident in achieving long-term growth despite short-term losses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Initial Director's Interest Notice - James Barrie
|
23 Feb 2024 4:26PM |
$0.026 |
$0.010 |
fallen by
61.54%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Final Director's Interest Notice - Glenn Smith
|
23 Feb 2024 4:25PM |
$0.026 |
$0.010 |
fallen by
61.54%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
CLOSE OF SHORTFALL OFFER AND LEADERSHIP CHANGES
|
23 Feb 2024 3:48PM |
$0.026 |
$0.010 |
fallen by
61.54%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
UK SPORTS INSTITUTE SIGNS LANDMARK DEAL WITH HITIQ
|
20 Feb 2024 9:38AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Dec23 Quarterly Activities Report and Appendix 4C
|
31 Jan 2024 4:48PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Increased commercial activity across multiple verticals and demographics.
- Positive commercial outlook for the second half of 2024 financial year.
- Strategic partnership with AFL for head impact sensor technology and concussion management.
- Entry into the NRL market with an initial order from Sydney Roosters.
- Cash reserves of A$851k as of December 2023.
- Achieved important compliance milestone with ISO27001 certification.
- Ongoing collaborations with universities for concussion research.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
HITIQ SIGNS MULTI-PRODUCT DEAL WITH AFL
|
31 Jan 2024 4:46PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- HitIQ partners with AFL for the 2024 season.
- The partnership covers AFL, AFLW, VFL, and VFLW competitions.
- It represents 60% of HitIQ's FY 2023 operating revenues.
- The agreement includes concussion management and sensor technology.
- The collaboration aligns with Australian Senate recommendations.
- Contracts are structured as 12-month agreements.
- The partnership emphasizes player safety and health.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Trading Halt
|
30 Jan 2024 4:34PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by HitIQ Limited.
- Pending announcement of a new material contract.
- Trading halt effective until 1 February 2024 or announcement release.
- Board approval for the trading halt request.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Pause in Trading
|
30 Jan 2024 3:40PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
HIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Temporary pause in trading for HitIQ Limited.
- Trading pause announced on January 30, 2024.
- Securities identified by security code HIQ.
- Pause pending further announcement from the company.
- Announcement made by ASX Listings Compliance, represented by Laura Gomme.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Change of Director's Interest Notice - Matthew Clayworth
|
22 Jan 2024 3:10PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Application for quotation of securities - HIQ
|
22 Jan 2024 2:52PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Top 20 option holders - HIQO
|
22 Jan 2024 2:47PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$8 |
Distribution Schedule - HIQO
|
22 Jan 2024 2:34PM |
$0.017 |
$0.010 |
fallen by
41.18%
|
|